CELESTIAL

Celestial Biolabs Limited has informed the Exchange regarding 'Certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018 for the quarter ended 31st December, 2022'.

Celestial Biolabs Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30th September, 2022

Celestial Biolabs Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018 for the quarter ended 30th June, 2022

Celestial Biolabs Limited has informed the Exchange about Certificate under Reg.74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31st March, 2022

Celestial Biolabs Limited has informed the Exchange regarding Clarification on SEBI interim order.

Celestial Biolabs Limited has informed the Exchange that ''We are already manufacturing and marketing Premium products In Herbal and Nutraceuticals range. In view of our established marketing & distribution network in India, we have decided to introduce manufacturing and marketing of 21 life saving drugs in Allopathic range covering,. Antibiotics, Analgesic & Anti-pyretics; Antiulcerants; Anti-Hypertensives; Anti-Diabetics; Anti-Fungal; Anti-Allergic; Anti-Emetic; Calcium Supplement; Steroid; Immune Suppressant and Topical Application for Wound Infection & Neurological disorders.This will enha

Celestial Biolabs Limited has informed the Exchange that the Company has completed successfully pre-clinical study on mouse for finding out toxicity and efficacy for Herbal Biovita (A health drink). Human controlled clinical trial shall start in phases to complete the Dozier so that we can place this product globally. Biovita has been accepted by Indian market very well.

Celestial Biolabs Limited has informed the Exchange that the Board of Directors had in their meeting held on July 02, 2015 have considered and adopted the revised Balance Sheet as on March 31, 2015 due the reason of regrouping of accounts.

Celestial Biolabs Limited has informed the Exchange vide letter dated January 12, 2015 regarding "Celestial To Launch Patented Anti-Diabetic Product".

Celestial Biolabs Limited has informed the Exchange that Celestial Biolabs Ltd Hyderabad has launched Cadalmin Gae, a marine derived, developed, formulated clinically tested and patented natural product to treat arthritis ( all kinds of joint pain). The product has received remarkable response from doctors as well as patients. The product is very effective, safe and vegetarian. The product is quite affordable as the selling price of the product is 1/ 3rd of the chemically derived medicine available in the market being used for arthritis. In order to reach to all the affected people suffering

Celestial Biolabs Limited has informed the Exchange, vide letter dated September 19, 2013 a copy of corporate announcement titled "Launching of New Product - CADALMIN GAe".

Celestial Biolabs Limited has informed the Exchange that "Our Company has started production and marketing of 12 neutraceuticals in the domestic as well as overseas markets. We are glad to confirm that the products were developed through our in-house R & D".

Celestial Biolabs Limited has informed the Exchange that : " we have filed Twelve Patents for Herbal Medicines developed through in-house research facility recognized by Department of Science and Industrial Research, New Delhi ".

Celestial Labs Limited has informed the Exchange regarding outcome of the board meeting held on November 06, 2009 - Revised as follows: "In the intimation made to you on 06.11.2009 the number of warrants to be read as 22,00,000 instead of 8,45,000".

Celestial Labs Limited has informed the Exchange that "Celestial has added 50 members Technical team to work in Biopharma - SAP support with an order worth of US $ 1 Million business initially".

Celestial Labs Limited has informed the Exchange that the Company has been awarded by NSIC / Dun & Brad Street SME rating with SE2A HIGH rating during a recent appraisal done independently.

Celestial Labs Limited has informed the Exchange that : "Celestial Labs Ltd has acquired the contract Research of Rational Laboratories located at Nacharam, Hyderabad and Sandiego, USA. As a part of the agreement Celestial Labs acquires laboratory space of around 48000 sq. feet which substantially enhances the Celestial Labs pitch in Contract Research and Drug Discovery business".

Celestial Labs Limited has informed the Exchange that: "The company has acquired the channel partnership of Microsoft to strengthen Celestial ERP business. The main promoter of the Company, Dr .A.N. Singh is in the process transferring IPR rights worth total 11 crore as valued to the company. However, Dr.A.N.Singh entitlement is 8.175 crore out of which he shall claim worth Rs 2.5 crore shares not exceeding 5% on expended capital, balance will be subsequently claimed. The exercise shall immensely help the company to increase the business in the smaller and medium sectors of ERP business".